Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 7 (2010), Issue 1 (January)

  1. Radical prostatectomy for high-risk prostate cancer.
    Jpn J Clin Oncol, 40(1): 3-9. [Abstract] [Full-text]
  2. Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
    Jpn J Clin Oncol, 40(1): 79-84. [Abstract] [Full-text]
  3. Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.
    J Cell Physiol, 222(3): 546-55. [Abstract] [Full-text]
  4. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
    Int J Cancer, 126(5): 1166-76. [Abstract] [Full-text]
  5. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer.
    Cancer Res, 70(1): 347-56. [Abstract] [Full-text]
  6. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.
    Cancer Res, 70(1): 240-8. [Abstract] [Full-text]
  7. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.
    Cancer Res, 70(1): 229-39. [Abstract] [Full-text]
  8. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.
    J Nucl Med, 51(1): 31-6. [Abstract] [Full-text]
  9. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    J Natl Cancer Inst, 102(1): 39-46. [Abstract] [Full-text]
  10. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
    J Immunol, 184(2): 1092-101. [Abstract] [Full-text]
  11. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
    J Clin Oncol, 28(2): 340-7. [Abstract] [Full-text]
  12. Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 3' untranslated region.
    Biochem J, 425(3): 575-83. [Abstract] [Full-text]
  13. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.
    Oncogene, 29(2): 214-26. [Abstract] [Full-text]
  14. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer.
    Strahlenther Onkol, 186(1): 46-52. [Abstract] [Full-text]
  15. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.
    J Biol Chem, 285(4): 2368-74. [Abstract] [Full-text]
  16. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
    Cancer Chemother Pharmacol, 65(4): 811-5. [Abstract] [Full-text]
  17. Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer.
    Br J Cancer, 102(2): 403-13. [Abstract] [Full-text]
  18. Mutation analysis of the MSMB gene in familial prostate cancer.
    Br J Cancer, 102(2): 414-8. [Abstract] [Full-text]
  19. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.
    Br J Cancer, 102(2): 249-54. [Abstract] [Full-text]
  20. Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1.
    Clin Exp Med, 10(1): 51-7. [Abstract] [Full-text]
  21. Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.
    Clin Exp Metastasis, 27(1): 19-23. [Abstract] [Full-text]
  22. Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database.
    Am J Clin Nutr, 91(2): 440-8. [Abstract] [Full-text]
  23. Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection.
    AJR Am J Roentgenol, 194(2): 446-52. [Abstract] [Full-text]
  24. Repeat prostate biopsy accuracy: simulator-based comparison of two- and three-dimensional transrectal US modalities.
    Radiology, 254(2): 587-94. [Abstract] [Full-text]
  25. Dissecting the dynamics of serum prostate-specific antigen.
    Am J Clin Pathol, 133(2): 187-93. [Abstract] [Full-text]
  26. Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
    J Cancer Res Clin Oncol, 136(3): 379-86. [Abstract] [Full-text]
  27. Resonant Mie scattering (RMieS) correction of infrared spectra from highly scattering biological samples.
    Analyst, 135(2): 268-77. [Abstract] [Full-text]
  28. The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.
    J Virol, 84(4): 1874-80. [Abstract] [Full-text]
  29. Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies.
    Am J Surg Pathol, 34(2): 169-77. [Abstract] [Full-text]
  30. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
    J Urol, 183(2): 634-9. [Abstract] [Full-text]
  31. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    J Urol, 183(2): 539-44. [Abstract] [Full-text]
  32. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    J Urol, 183(2): 529-33. [Abstract] [Full-text]
  33. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
    J Urol, 183(2): 534-8. [Abstract] [Full-text]
  34. An update of the Gleason grading system.
    J Urol, 183(2): 433-40. [Abstract] [Full-text]
  35. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
    J Urol, 183(2): 520-7. [Abstract] [Full-text]
  36. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.
    J Urol, 183(2): 546-50. [Abstract] [Full-text]
  37. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
    Hum Pathol, 41(2): 281-5. [Abstract] [Full-text]
  38. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
    Hum Pathol, 41(2): 214-22. [Abstract] [Full-text]
  39. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.
    Cancer Immunol Immunother, 59(4): 529-40. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience